Amended Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K/A

 


 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 4, 2004

 


 

Arrowhead Research Corporation

(Exact name of registrant as specified in its charter)

 


 

Delaware   0-21898   46-0408024

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(I.R.S. Employer

Identification No.)

 

1118 East Green Street, Pasadena, CA   91106
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (626) 792-5549

 

Not Applicable

(Former name or former address, if changed since last report)

 



Arrowhead Research Corporation (the “Arrowhead Research”) hereby amends Item 7 of its Current Report on Form 8-K dated June 18, 2004 to include the financial statement information indicated in Item 7 below, as required by Item 7(a) of Form 8-K and Item 7(b) of Form 8-K. The information was excluded from the original filing in reliance on Items 7(a)(4) and 7(b)(2), respectively, of Form 8-K. The original June 18, 2004 filing of Form 8-K described the acquisition of Insert Therapeutics, Inc. (“Insert Therapeutics”), a Pasadena-based company focused on designing, developing and commercializing delivery-enhanced therapeutics using its patented class of polymeric delivery systems.

 

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

 

ITEM 7 (a) FINANCIAL STATEMENTS OF BUSINESS ACQUIRED

 

The audited financial statements for Insert as of December 31, 2003 and 2002, together with a report of independent auditors are hereby filed as part of this Report on Form 8-K/ A and are included in Exhibit 99.1. Unaudited financial statements for Insert Therapeutics as of March 31, 2004 and 2003 are also included.

 

ITEM 7 (b). PRO FORMA FINANCIAL STATEMENTS

 

The following unaudited pro forma condensed combined financial information of the Company, are hereby filed as part of this Report on Form 8-K/ A and are included in Exhibit 99.2:

 

a )   Unaudited pro forma condensed combined balance sheet as of March 31, 2004.
b )   Unaudited pro forma condensed combined statements of operations for the six months ended March 31, 2004.
c )   Unaudited pro forma condensed combined statements of operations for the year ended September 30, 2003 (combining pro forma information for Insert Therapeutics as of the year ended December 31, 2003).
d )   Notes to unaudited pro forma condensed combined financial statements.

 

ITEM 7 (c). EXHIBITS

 

Exhibit No.

 

Description  


23.1   Consent of Independent Auditors of Insert Therapeutics, Inc.
99.1   Independent Auditor’s Report and Financial Statements of Insert Therapeutics, Inc.
99.2   Unaudited Pro Forma Condensed Combined Financial Statements of Arrowhead Research Corporation


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 11, 2004

 

ARROWHEAD RESEARCH CORPORATION

By:

 

/s/ R. Bruce Stewart


   

R. Bruce Stewart, President

Consent of Independent Auditors of Insert Therapeutics, Inc.

Exhibit 23.1

 

CONSENT OF INDEPENDENT AUDITORS

 

We consent to the use of our report dated July 13, 2004, with respect to the financial statements of Insert Therapeutics, Inc. included in the Current Report on Form 8-K/A of Arrowhead Research Corporation.

 

/s/    ROSE, SNYDER & JACOBS

 

Rose, Snyder & Jacobs

A Corporation of Certified Public Accountants

Encino, California

August 10, 2004

Independent Auditor's Report and Financial Statements of Insert Therapeutics

Exhibit 99.1

 

INDEPENDENT AUDITORS’ REPORT

 

The Board of Directors

Insert Therapeutics, Inc.

Pasadena, California

 

We have audited the accompanying balance sheets of Insert Therapeutics, Inc., as of December 31, 2003 and 2002, and the statements of operations and cash flows for the years then ended. These financial statements are the responsibility of Insert Therapeutic, Inc.’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Insert Therapeutics, Inc. as of December 31, 2003 and 2002, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

 

/s/    ROSE, SNYDER & JACOBS

 

Rose, Snyder & Jacobs

A Corporation of Certified Public Accountants

Encino, California

July 13, 2004


Insert Therapeutics, Inc.

Balance Sheets

As of December 31, 2003 and 2002

 

     December 31,
2003


    December 31,
2002


 
ASSETS                 

CURRENT ASSETS

                

Cash

   $ 520,215     $ 513,642  

Grant receivable, net of allowance for doubtful account of $0

     7,461       —    

Prepaids and other current assets

     9,958       —    
    


 


TOTAL CURRENT ASSETS

     537,634       513,642  
    


 


PROPERTY & EQUIPMENT

                

Computers and office equipment

     60,621       60,621  

Furniture

     22,677       22,677  

Research Equipment

     595,269       595,269  

Software

     12,955       12,280  

Leasehold Improvements

     84,239       84,239  
    


 


       775,761       775,086  

Less: Accumulated depreciation & amortization

     (456,337 )     (312,265 )
    


 


NET PROPERTY & EQUIPMENT

     319,424       462,821  
    


 


OTHER ASSETS

                

Restricted cash

     50,773       89,010  
    


 


TOTAL OTHER ASSETS

     50,773       89,010  
    


 


TOTAL ASSETS

   $ 907,831     $ 1,065,473  
    


 


LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)                 

CURRENT LIABILITIES

                

Accounts payable

   $ 45,099     $ 28,445  

Accrued expenses

     52,466       63,043  

Payroll liabilities

     32,449       35,488  
    


 


TOTAL CURRENT LIABILITIES

     130,014       126,976  
    


 


LONG TERM LIABILITIES

                

Notes payable

     2,105,869       508,003  
    


 


TOTAL LONG TERM LIABILITIES

     2,105,869       508,003  
    


 


TOTAL LIABILITIES

     2,235,883       634,979  
    


 


SHAREHOLDERS’ EQUITY (DEFICIT)

                

Common Stock

     13,670       13,670  

Preferred Stock

     3,000,000       3,000,000  

Accumulated deficit

     (4,341,722 )     (2,583,176 )
    


 


TOTAL SHAREHOLDERS’ EQUITY (DEFICIT)

     (1,328,052 )     430,494  
    


 


TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)

   $ 907,831     $ 1,065,473  
    


 



Insert Therapeutics, Inc.

Statement of Operations

For the Years Ended December 31, 2003 and 2002

 

     December 31,
2003


    December 31,
2002


 

REVENUE

   $ 377,212     $ 1,000,000  

OPERATING EXPENSES

                

Salaries

     849,837       654,299  

Consulting

     186,984       177,141  

General and administrative expenses

     310,969       424,818  

Research and development

     696,581       751,534  
    


 


TOTAL OPERATING EXPENSES

     2,044,371       2,007,792  
    


 


OPERATING LOSS

     (1,667,159 )     (964,602 )
    


 


OTHER INCOME (EXPENSES)

                

Interest income

     6,480       18,592  

Interest expense

     (97,867 )     (13,562 )
    


 


TOTAL OTHER INCOME (EXPENSES)

     (91,387 )     5,030  
    


 


NET LOSS

   $ (1,758,546 )   $ (1,002,762 )
    


 



Insert Therapeutics, Inc.

Statement of Cash Flows

For the Years Ended December 31, 2003 and 2002

 

     2003

    2002

 

CASH FLOWS FROM OPERATING ACTIVITIES:

                

Net loss

   $ (1,758,546 )   $ (1,002,762 )

Adjustment to reconcile net loss to net cash used in operating activities:

                

Depreciation and amortization

     144,072       169,278  

Decrease (increase) in grant receivable

     (7,461 )     —    

Decrease (increase) in prepaid and other assets

     28,280       —    

Decrease (increase) in accounts payable

     16,654       4,013  

Decrease (increase) in other liabilities

     84,249       59,420  
    


 


NET CASH USED IN OPERATING ACTIVITIES

     (1,492,752 )     (770,051 )
    


 


CASH FLOWS FROM INVESTING ACTIVITIES:

                

Purchase of property & equipment

     (675 )     (59,816 )
    


 


NET CASH USED IN INVESTING ACTIVITIES

     (675 )     (59,816 )
    


 


CASH FLOWS FROM FINANCING ACTIVITIES:

                

Net proceeds from issuance of note payable

     1,500,000       500,000  

Payments on notes payable

     0       (118,017 )
    


 


NET CASH PROVIDED BY FINANCING ACTIVITIES

     1,500,000       311,983  
    


 


NET INCREASE (DECREASE) IN CASH

     6,573       (517,884 )
    


 


CASH AT BEGINNING OF PERIOD

     513,642       1,031,526  
    


 


CASH AT END OF PERIOD

   $ 520,215     $ 513,642  
    


 


Supplementary disclosures:

                

Interest paid

   $ —       $ —    
    


 


Income tax paid

   $ 800     $ 800  
    


 



Insert Therapeutics, Inc.

Notes to Financial Statements

December 31, 2003

 

NOTE 1. ORGANIZATION

 

Headquartered in Pasadena, California, Insert Therapeutics, Inc. (“Insert Therapeutics”) was incorporated in the state of Delaware in February 2000. Under the direction of Dr. Mark Davis, a professor of chemical engineering at Caltech, Insert Therapeutics is currently expanding and leveraging its platform technology, Cyclosert, through an internal small-molecule drug delivery development program, a gene-therapy collaboration with San Diego-based Canji, Inc., a subsidiary of Schering-Plough, and grants in both areas from the National Cancer Institute. Insert has designed a novel class of nanoscale cyclodextrin polymers that incorporate optimal properties for intracellular systemic delivery of a broad range of therapeutics. These polymers can be designed to fit the size of the molecule or drug to be delivered. Cyclosert’s linear cyclodextrin-containing polymers can be designed to be neutral, positively charged or negatively charged. This feature is unique to Cyclosert technology and provides great flexibility for formulation and delivery. Cyclosert polymers have been synthesized at molecular weights ranging up to 150 kD, allowing for systemic drug delivery with the potential to slow renal clearance, enhance circulation time and improve passive accumulation of active drug at the target tissue. When used in these Notes to Financial Statements, the term “Technology” refers to Insert Therapeutics’ Cyclosert and the company’s related drug delivery development program.

 

License Agreement

 

On May 22, 2000, Insert Therapeutics entered into a license agreement with the California Institute of Technology (“Caltech”) whereby Insert Therapeutics obtained an exclusive worldwide license to certain patents and future improvements to the patented technology. Insert Therapeutics was also given a nonexclusive worldwide license to proprietary information and research tools directly relevant to development of the Technology. However, the technology covered by this nonexclusive license is not subject to patent protection.

 

Liquidity

 

Insert Therapeutics has incurred recurring losses and negative cash flows from operations. Insert Therapeutics obtained grants from the National Cancer Institute in 2003, which are expected to help fund a portion of Insert Therapeutics’ research. In June 2004, Insert Therapeutics entered into an agreement with Arrowhead Research Corporation (“Arrowhead Research”), a Pasadena, California based, publicly- held nanotechnology company, under which Arrowhead Research purchased 24,496,553 shares of voting, Series B Preferred Stock, representing approximately 62% of the voting securities of Insert Therapeutics, for $1,000,000 paid on the closing date of June 4, 2004. Management believes that the $1,000,000 proceeds from the stock sale will be sufficient to fund ongoing operations of Insert Therapeutics through at least December 31, 2004.

 

Also on June 4, 2004, Insert Therapeutics executed a Stock Purchase Agreement with the California Institute of Technology, whereby Caltech purchased 1,224,828 shares of Series B Preferred Stock for $250,000.

 

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Cash and Cash Equivalents

 

Insert Therapeutics has classified all highly liquid investments with an original maturity of three months or less as cash equivalents. Included in cash at December 31, 2003 is $485,584 in excess of the FDIC insured amount.


Restricted Cash

 

Restricted cash in the amount of $50,773 and $89,010 at December 31, 2003 and 2002 respectively is to secure a facility lease, which is now on a month-month basis.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, and the fair value of stock options. Actual results could differ from those estimates.

 

Revenue Recognition

 

Insert Therapeutics’ primary source of revenue is from private contributions as part of its research collaborations with pharmaceutical companies. Insert Therapeutics was also awarded a grant of $236,441 for the period from July 2003 through June 2004 and $244,780 for the period from July 2004 through June 2005. These grants are recognized as revenue as the funds are expended in accordance with the terms of the grant, and, for the year ended December 31, 2003, Insert Therapeutics recognized revenue from the grant in the amounts of $52,213.

 

Financial Instruments

 

Insert Therapeutics’ financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which approximates their fair value, due to the relatively short maturity of these instruments. As of December 31, 2003 and 2002, Insert Therapeutics’ notes payable have stated borrowing rates that are consistent with those currently available to Insert Therapeutics and, accordingly, Insert Therapeutics believes the carrying value of these debt instruments approximates their fair value.

 

Property and Equipment

 

Fixed assets are stated at cost less accumulated depreciation. Expenditures over $1,000 that would increase the value or extend the useful life of property and equipment are capitalized. Depreciation is provided on a straight-line basis over the estimated useful life of the assets that range from 3 years to 7 years. Leasehold improvements are amortized over the original term of the lease that expired on April 1, 2003. Insert Therapeutics continues to occupy its original office and lab space at 2585 Nina Street, Pasadena, CA 91107, on a month-to-month basis.

 

Stock-Based Compensation

 

Insert Therapeutics accounts for employee stock option grants in accordance with Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees and related interpretations (APB 25), and has adopted the “disclosure only” alternative described in Statement of Financial Accounting Standards (SFAS) No. 123, Accounting for Stock-Based Compensation, amended by SFAS No. 148 Accounting for Stock Based Compensation-Transition and Disclosure.

 

SFAS No. 123, Accounting for Stock-Based Compensation, requires pro forma information regarding net income (loss) using compensation that would have been incurred if Insert Therapeutics had accounted for its employee stock options under the fair value method of that statement. Options to purchase 80,000 and 580,000 shares of Insert Therapeutics were granted during the years ended December 31, 2003 and 2002, respectively. The fair value of options granted in the years ended December 31, 2003 and 2002


were estimated at $2,377 and $18,857, respectively, as of the date of grant in accordance with the Black-Scholes Option pricing model with the following assumptions:

 

     2003

    2002

 

Risk free interest rate

   3.27 %   3.03 %

Stock volatility factor

   0.01     0.01  

Weighted average expected option life

   5 years     5 years  

Expected dividend yield

   None     None  

 

The pro forma net loss and loss per share had Insert Therapeutics accounted for the options using FAS 123 would have been as follows:

 

     2003

    2002

 

Net loss as reported

   $ (1,758,546 )   $ (1,002,762 )

Deduct: Total stock based employee compensation expense determined under fair value based method for all awards

     (13,085 )     (10,223 )
    


 


Pro forma net loss

   $ (1,771,631 )   $ (1,012,985 )
    


 


 

Net Loss Per Share

 

Net loss per common share is computed using the weighted average number of common shares outstanding during the periods presented. Options to purchase shares of Insert Therapeutics’ stock under its stock option plan and warrants may have a dilutive effect on Insert Therapeutics’ earnings per share in the future but are not included in the calculation for fiscal 2002 and 2003 because they have an antidilutive effect in these periods.

 

Income Taxes

 

Insert Therapeutics uses the liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to financial statements carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The measurement of deferred tax assets and liabilities is based on provisions of applicable tax law. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance based on the amount of tax benefits that, based on available evidence, is not expected to be realized.

 

Recent Accounting Pronouncements

 

In December 2002, the FASB issued SFAS No. 148, “Accounting for Stock-Based Compensation - Transition and Disclosure” (“SFAS No. 148”), which amends SFAS No. 123. SFAS No. 148 amends the disclosure requirements in SFAS No. 123 for stock-based compensation for annual periods ending after December 15, 2002 and interim periods beginning after December 15, 2002. The disclosure requirements apply to all companies, including those that continue to recognize stock-based compensation under APB No. 25. Effective for financial statements for fiscal years ending after December 15, 2002, SFAS No. 148 also provides three alternative transition methods for companies that choose to adopt the fair value measurement provisions of SFAS No. 123. Insert Therapeutics continues to recognize stock-based compensation under APB No. 25.


In December 2002, the FASB issued Interpretation No. 45 (FIN 45), Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others. FIN 45 requires a guarantor to make additional disclosures in its interim and annual financial statements regarding the guarantor’s obligations. In addition, FIN 45 requires, under certain circumstances, that a guarantor recognize, at the inception of the guarantee, a liability for the fair value of the obligation undertaken when issuing the guarantee. Insert Therapeutics did not have any outstanding guarantees that needed to be recorded upon adoption of FIN 45.

 

In May 2003, the FASB issued SFAS 150, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity. SFAS 150 improves the accounting for certain financial instruments that, under previous guidance, issuers could account for as equity. SFAS 150 requires that those instruments be classified as liabilities in statements of financial position. SFAS 150 is effective for interim periods beginning after June 15, 2003. Insert Therapeutics does not expect this statement to have a material impact on its financial statements.

 

NOTE 3. INCOME TAXES

 

At December 31, 2003, Insert Therapeutics had available for federal and state income tax purposes, net operating loss carryforwards that are subject to significant limitations because of statutory “ownership changes.”

 

The difference between Insert Therapeutics’ effective income tax rate and the statutory federal rate for the years ended December 31, 2003 and 2002 relates primarily to losses incurred for which no tax benefit was recognized, due to the uncertainty of its realization. The valuation allowance was recorded for 100% of the deferred tax assets, representing an increase of approximately $700,000 and $400,000 for the years ended December 31, 2003 and 2002, respectively.

 

A reconciliation of income tax expense that would result from applying the domestic Federal statutory rate to pre-tax income, with federal income tax expense presented in the financial statements is as follows:

 

     2003

    2002

 

Income tax benefit computed at U.S. federal statutory rate (34%)

   $ 600,000     $ 340,000  

State income taxes, net of benefit federal taxes

     100,000       60,000  

Less valuation allowance

     (700,000 )     (400,000 )
    


 


Income tax expense

   $ —       $ —    
    


 


 

NOTE 4. CAPITAL STOCK

 

Insert Therapeutics is authorized to issue 15,000,000 common shares at par value of $0.0001 per share, of which 6,161,522 shares were outstanding as of December 31, 2003. Insert Therapeutics is also authorized to issue 6,000,000 shares of Preferred Stock.

 

In August 2000 and January 2001, Insert Therapeutics issued an aggregate of 3,375,000 shares of voting, Convertible Preferred Series A preferred stock (the “Series A”), par value $0.0001 per share, to accredited investors for an aggregate purchase price of $3,000,000. All of the Series A was converted, on a 1-for-1 basis, into 3,375,000 shares of common stock of Insert Therapeutics in June 2004. Before conversion, holders of the Series A had full participation rights with the common shares and also were entitled to noncumulative dividends in the amount of 10% of the original issue price, when and if declared by the Board of Directors. As of December 31, 2003 and 2002, no dividends or distributions had been made to the Series A holders.

 

In June 2004, Insert Therapeutics filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of California authorizing 25,721,381 shares of Series B Preferred Stock, par value 0.0001 per share. The Series B Preferred Stock is voting stock and votes together with the Common Stock on an as converted basis. However, extraordinary corporate events, such as a sale of assets or stock, or a significant debt commitment, must be approved by the vote of the Series B Preferred Stock, voting on its own as a single class. The terms of the Series B Preferred Stock also entitle the holder of the Series B Preferred Stock to elect a majority of Insert Therapeutics’ Board of Directors, and, therefore, the holders of Series B Preferred Stock exercise significant control over Insert Therapeutics and have the ability to direct the company’s strategic and business development.

 

Upon a liquidation event, holders of the Series B Preferred Stock are entitled either to participate with the Common Stock on an as converted basis, or to a liquidation preference equal to the initial purchase price along with any declared but unpaid dividends or distributions. In June 2004, Insert Therapeutics issued an aggregate of 25,721,381 shares of Series B Preferred Stock to Arrowhead Research and the California Institute of Technology for an aggregate purchase price at closing of $1,250,000.


NOTE 5. RELATED PARTY TRANSACTIONS

 

On September 1, 2002 Insert Therapeutics entered into a Consulting Agreement with Dr. Mark Davis, who is also a Director of Insert Therapeutics, whereby Dr. Davis provides consulting services regarding scientific research and development of Insert Therapeutics’ proposed products in exchange for a monthly retainer of $5,000. Beginning June 1, 2004, the monthly retainer was increased to $7,000 and the term of the Agreement was extended until December 31, 2005.

 

Insert Therapeutics made two successive annual gifts to Dr. Davis’ laboratories at Caltech of $100,000 each in 2002 and 2003, respectively.

 

NOTE 6. NOTES PAYABLE

 

Insert Therapeutics had Convertible Preferred Notes issued to J.J. Jacobs Enterprises, LLC and California Technology Partners, LP totaling $2,000,000 and $500,000 at December 31, 2003 and 2002, respectively. These notes bore interest at 8.50% per annum and initially matured on September 18, 2004, or on the date of a consummation of a liquidation event as defined in the notes, whichever is sooner. Interest totaling $105,869 and $8,003 had been capitalized to these notes at December 31, 2003 and 2002, respectively. These notes were secured by all tangible and intangible assets of Insert Therapeutics. As a condition to the sale of Insert Therapeutics’ shares to Arrowhead Research, all amounts owing under these notes were converted into four million shares of Insert Therapeutics’ common stock in June 2004.

 

NOTE 7. STOCK OPTIONS AND WARRANTS

 

Insert Therapeutics has a Stock Option/Stock Issuance Plan that provides for the granting of stock options to its employees and others providing services to Insert Therapeutics. The maximum number of shares of Common Stock that can be issued over the term of the Plan shall not exceed 635,000 shares. The plan was amended on September 23, 2002 to increase the number of shares under the plan to 1,200,000. As a condition to the sale of Insert Therapeutics’ shares to Arrowhead Research, the plan was amended on June 4, 2004 to increase the number of shares under the plan to 9,000,000.

 

A summary of Insert Therapeutics’ stock option activity and related information follows:

 

    

Year ended

December 31, 2003


  

Year ended

December 31, 2002


     Options

   Weighted
average
exercise
price


   Options

   Weighted
average
exercise
price


Outstanding -beginning of year

   935,000    $ 0.32    355,000    $ 0.45

Granted

   80,000      0.20    580,000      0.23

Exercised

   —        —      —        —  

Forfeited

   30,625      0.45    —        —  
    
  

  
  

Outstanding - end of year

   984,375    $ 0.30    935,000    $ 0.32
    
  

  
  

Exercisable at the end of year

   514,464    $ 0.37    272,760    $ 0.42
    
  

  
  


The weighted average remaining contractual life of options as of December 31, 2003 was as follows:

 

Exercise price  


   Number of options
outstanding


   Weighted average
remaining contractual
life (years)


   Options exercisable

$0.20 - 0.45

   984,375    8.2    514,464

 

Stock Warrants

 

The following warrants were outstanding and exercisable at December 31, 2003:

 

Number of shares  


   Exercise Price

   Expiration date

20,000

   $ 0.89 per share    July 25, 2007

30,000

   $ 0.45 per share    September 1, 2007

 

NOTE 8. CONSULTING AGREEMENTS

 

On July 1, 2002 Insert Therapeutics entered into a Consulting Agreement with NEOLOGIX, a California corporation, to provide general corporate and business consulting services as requested from time to time by Insert Therapeutics. Compensation paid to NEOLOGIX, based on a hourly schedule, amounted to $71,000 and $64,825 for the years ended December 31, 2003 and 2002, respectively. This Consulting Agreement was modified, effective June 1, 2004, such that Insert Therapeutics pays NEOLOGIX a fixed monthly retainer of $14,583 in lieu of hourly billing. The Consulting Agreement continues on a month-to-month basis until cancelled by either party with ten (10) days written notice.

 

Also see “NOTE 5. RELATED PARTY TRANSACTIONS” for discussion of Consulting Agreement with Dr. Mark Davis.

 

NOTE 9. SUBSEQUENT EVENTS

 

On June 4, 2004, Insert Therapeutics executed a Stock Purchase Agreement with Arrowhead Research, a Pasadena-based, publicly-held nanotechnology company, whereby Arrowhead Research obtained a majority interest in Insert Therapeutics.

 

Pursuant to the Agreement, Arrowhead Research purchased 24,496,553 shares of voting, Series B Preferred Stock, representing approximately 62% of the voting securities of Insert Therapeutics, for $1,000,000, paid on the closing date of June 4, 2004. In conjunction with the stock sale, Arrowhead Research entered into a related Agreement to Provide Additional Capital, pursuant to which Arrowhead Research may choose to make additional capital contributions as follows $1,000,000 on December 1, 2004; and $3,000,000 upon the attainment of certain milestones in the further development of Insert Therapeutics’ business. If Arrowhead Research chooses not to make an additional capital contribution, Arrowhead Research will forfeit a proportionate number of shares.

 

Also on June 4, 2004, Insert Therapeutics executed a Stock Purchase Agreement with the California Institute of Technology, whereby Caltech purchased 1,224,828 shares of Series B Preferred Stock for $250,000.


Insert Therapeutics, Inc.

Condensed Balance Sheets

As of March 31, 2004 and 2003

(Unaudited)

 

     March 31,
2004


    March 31,
2003


 
ASSETS                 

CURRENT ASSETS

                

Cash

   $ 144,020     $ 542,224  

Grant receivable, net of allowance for doubtful account of $0

     9,000       —    
    


 


TOTAL CURRENT ASSETS

     153,020       542,224  
    


 


PROPERTY & EQUIPMENT

                

Computers and office equipment

     60,621       60,621  

Furniture

     22,677       22,677  

Research Equipment

     595,269       595,269  

Software

     12,955       12,955  

Leasehold Improvements

     84,239       84,239  
    


 


       775,761       775,761  

Less: Accumulated depreciation & amortization

     (490,902 )     (352,641 )
    


 


NET PROPERTY & EQUIPMENT

     284,859       423,120  
    


 


OTHER ASSETS

                

Restricted cash

     50,773       89,010  

Prepaid & other assets

     6,000       —    
    


 


TOTAL OTHER ASSETS

     56,773       89,010  
    


 


TOTAL ASSETS

   $ 494,652     $ 1,054,354  
    


 


LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)                 

CURRENT LIABILITIES

                

Accounts payable

   $ 16,562     $ 7,487  

Accrued expenses

     20,020       63,953  

Payroll liabilities

     30,332       37,151  
    


 


TOTAL CURRENT LIABILITIES

     66,914       108,591  
    


 


LONG TERM LIABILITIES

                

Note payable

     2,148,750       1,019,409  
    


 


TOTAL LONG TERM LIABILITIES

     2,148,750       1,019,409  
    


 


TOTAL LIABILITIES

     2,215,664       1,128,000  
    


 


SHAREHOLDERS’ EQUITY (DEFICIT)

                

Capital Stock

     13,670       13,670  

Preferred Stock

     3,000,000       3,000,000  

Accumulated deficit

     (4,734,682 )     (3,087,316 )
    


 


TOTAL SHAREHOLDERS’ EQUITY (DEFICIT)

     (1,721,012 )     (73,646 )
    


 


TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)

   $ 494,652     $ 1,054,354  
    


 



Insert Therapeutics, Inc.

Condensed Statements of Operations

For the Three Months Ended March 31, 2004 and 2003

(Unaudited)

 

     March 31,
2004


    March 31,
2003


 

REVENUE

   $ 13,722     $ —    

OPERATING EXPENSES

                

Salaries

     218,044       241,460  

Consulting

     39,238       45,919  

General and administrative expenses

     43,227       90,521  

Research and development

     63,776       115,845  
    


 


TOTAL OPERATING EXPENSES

     364,285       493,745  
    


 


OPERATING LOSS

     (350,563 )     (493,745 )
    


 


OTHER INCOME (EXPENSES)

                

Interest income

     483       1,607  

Interest expense

     (42,880 )     (12,002 )
    


 


TOTAL OTHER INCOME (EXPENSES)

     (42,397 )     (10,395 )
    


 


NET LOSS

   $ (392,960 )   $ (504,140 )
    


 



Insert Therapeutics, Inc.

Condensed Statements of Cash Flows

For the Three Months Ended December 31, 2004 and 2003

(Unaudited)

 

     March 31,
2004


    March 31,
2003


 

CASH FLOWS FROM OPERATING ACTIVITIES:

                

Net loss

   $ (392,960 )   $ (504,140 )

Adjustment to reconcile net loss to net cash used in operating activities:

                

Depreciation and amortization

     34,565       40,376  

Decrease (increase) in grant receivable

     (1,539 )     —    

Decrease (increase) in prepaid and other assets

     3,958       —    

Decrease (increase) in accounts payable

     (28,537 )     (20,958 )

Decrease (increase) in accrued expenses

     10,435       12,316  

Decrease (increase) in other liabilities

     (2,117 )     1,663  
    


 


NET CASH USED IN OPERATING ACTIVITIES

     (376,195 )     (470,743 )
    


 


CASH FLOWS FROM INVESTING ACTIVITIES:

                

Purchase of property & equipment

     —         (675 )
    


 


NET CASH USED IN INVESTING ACTIVITIES

     —         (675 )
    


 


CASH FLOWS FROM FINANCING ACTIVITIES:

                

Net proceeds from issuance of common stock

     —            

Net proceeds from issuance of note payable

     —         500,000  
    


 


NET CASH PROVIDED BY FINANCING ACTIVITIES

     —         500,000  
    


 


NET INCREASE (DECREASE) IN CASH

     (376,195 )     28,582  
    


 


CASH AT BEGINNING OF PERIOD

     520,215       513,642  
    


 


CASH AT END OF PERIOD

   $ 144,020     $ 542,224  
    


 


Supplementary disclosures:

                

Interest paid

   $ —       $ —    
    


 


Income tax paid

   $ 800     $ 800  
    


 



Insert Therapeutics, Inc.

Notes to Condensed Unaudited Financial Statements

March 31, 2004

 

NOTE 1. BASIS OF PRESENTATION

 

The accompanying financial statements of Insert Therapeutics, Inc. (“Insert Therapeutics”) presented in this report should be read in conjunction with Insert Therapeutics’ financial statements for the years ended December 31, 2003 and 2002, and notes thereto, included in this Current Report 8-K/A as filed by Arrowhead Research Corporation (“Arrowhead Research”). The accompanying unaudited condensed financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2004 and 2003 are not necessarily indicative of the results that may be expected for the year ended December 31, 2004.

 

NOTE 2. SUBSEQUENT EVENTS

 

On June 4, 2004, the Company executed a Stock Purchase Agreement (the “Agreement”) with Arrowhead Research, a Pasadena, California-based, publicly-held nanotechnology company, whereby Arrowhead Research obtained a majority interest in Insert Therapeutics.

 

Pursuant to the Agreement, Arrowhead Research purchased 24,496,553 shares of voting, newly-issued Series B Preferred Stock, representing approximately 62% of the voting securities of Insert Therapeutics, for $1,000,000, paid on the closing date of June 4, 2004. In conjunction with the stock sale, Arrowhead Research entered into a related Agreement to Provide Additional Capital, pursuant to which Arrowhead may choose to make additional capital contributions as follows: $1,000,000 on December 1, 2004; and $3,000,000 upon the attainment of certain milestones in the further development of Insert Therapeutics’ business. If Arrowhead Research chooses not to make an additional capital contribution, Arrowhead Research will forfeit a proportionate number of shares.

 

Also on June 4, 2004, the Company executed a Stock Purchase Agreement with the California Institute of Technology, whereby Caltech purchased 1,224,828 shares of Series B Preferred Stock for $250,000.

Unaudited Pro Forma Condensed Combined Financial Statements-Arrowhead Research

Exhibit 99.2

 

ARROWHEAD RESEARCH CORPORATION

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENTS

 

On June 4, 2004, Arrowhead Research executed a Stock Purchase Agreement (the “Agreement”) with Insert Therapeutics, Inc., (“Insert Therapeutics”) a Pasadena-based company focused on designing, developing and commercializing delivery-enhanced therapeutics, using its patented class of polymeric delivery systems, whereby Arrowhead Research obtained a majority interest in Insert Therapeutics.

 

Pursuant to the Agreement, Arrowhead Research purchased 24,496,553 shares of voting, newly-issued Series B Preferred Stock, representing approximately 62% of the voting securities of Insert Therapeutics, for $1,000,000, paid on the closing date of June 4, 2004. In conjunction with the stock sale, Arrowhead Research entered into a related Agreement to Provide Additional Capital, pursuant to which Arrowhead Research may choose to make additional capital contributions as follows: $1,000,000 on December 1, 2004; and $3,000,000 upon the attainment of certain milestones in the further development of Insert Therapeutics’ business. If Arrowhead Research chooses not to make an additional capital contribution, Arrowhead Research will forfeit a proportionate number of shares.

 

The unaudited pro forma condensed combined balance sheet is presented as if the acquisition had taken place on March 31, 2004. The unaudited pro forma condensed combined statement of operations for the year ended September 30, 2003, combines Arrowhead Research’s statement of operations for the period from May 7, 2003 (inception date) and ended September 30, 2003 with the statement of operations of Insert Therapeutics for the year ended December 31, 2003 and is presented to reflect the acquisition as if it had occurred as of January 1, 2003.

 

The unaudited pro forma condensed combined statement of operations for the six months ended March 31, 2004, combines Arrowhead Research’s statement of operations for the six months ended March 31, 2004 with the statement of operations of Insert Therapeutics for the same period. The unaudited pro forma condensed combined statements of operation for the six months ended March 31, 2004 is presented to reflect the acquisition of Insert Therapeutic as if it had occurred on October 1, 2003. Due to the discrepancy in fiscal year ends of the companies, the operations of Insert Therapeutics for the three months ended December 31, 2003 are included in the presentation of both the pro forma condensed combined statement of operations for the six months ended March 31, 2004, as well as the year ended September 30, 2003.

 

The unaudited pro forma condensed combined financial information is based on the historical financial statements of Arrowhead Research and Insert Therapeutics, giving effect to the aquisition under the purchase method of accounting and the assumptions and adjustments in the accompanying notes to the unaudited pro forma condensed combined financial statements. The pro forma adjustments are based on management’s estimates of the value of the tangible and intangible assets acquired.

 

The accompanying financial statements of Insert Therapeutics presented in this report should be read in conjunction with Insert Therapeutics’ financial statements and footnotes for the years ended December 31, 2003 and 2002 thereto included in the Current Report 8-K/A, as filed by Arrowhead Research. The unaudited pro forma condensed combined financial statements should also be read in conjunction with the historical financial statements of Arrowhead Research, included in Arrowhead Research’s Form 10-KSB and any amendments thereof for the year ended September 30, 2003, and in Arrowhead Research’s Form 10-QSB, and any amendments thereof, for the six months ended March 31, 2004 filed with the Securities and Exchange Commission.

 

The acquisition was accounted for using the purchase method of accounting, and accordingly, the assets acquired have been recorded at their estimated fair values as of the date of the acquisition. These amounts have been recorded based upon preliminary estimates as of March 31, 2004. The unaudited pro forma financial data are based on the assumptions and adjustments available at the time of the filing


of this Form 8-K/A, as described in the accompanying notes, which Arrowhead Research believes are reasonable. The fair value of the consideration will be allocated to the net assets acquired based upon the fair values of such net assets at the effective date of the acquisition. The allocation presented here is preliminary, subject to change as additional information is received.

 

The unaudited condensed combined pro forma statement of operations does not purport to represent what Arrowhead Research’s results of operations actually would have been if the events described above had occurred as of the dates indicated or what Arrowhead Research’s results will be for any future periods. The unaudited condensed combined pro forma financial statements are based upon assumptions, estimates and adjustments that Arrowhead Research believes are reasonable and are intended for informational purposes only. The future consolidated financial position and results of operations will differ, potentially significantly, from the pro forma amounts reflected herein because of a variety of factors, including access to additional information and changes in values not currently identified. Further adjustments to the acquired assets will be reflected as a change in goodwill.

 

The unaudited pro forma adjustments do not reflect any operating efficiencies and related cost savings that could result with respect to the combined companies. The pro forma adjustments do not include any adjustments to historical revenue for any future price or product offering changes nor any adjustments to selling, marketing or any other expenses for any future operating changes.


ARROWHEAD RESEARCH CORPORATION

PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

 

Arrowhead Research Corporation

Unaudited Pro Forma Condensed, Combined Balance Sheet

As of March 31, 2004

 

     Arrowhead

    Insert

    Adjustments

    Pro Forma

 

ASSETS

                              

CURRENT ASSETS

                              

Cash and Cash Equivalents

   $ 10,330,701     $ 144,020           $ 10,474,721  

Marketable Securities

     807,628       —               807,628  

Grant receiveable

     —         9,000             9,000  

Other receivables

     145       —               145  

Prepaid expenses

     360,855       —               360,855  
    


 


       


TOTAL CURRENT ASSETS

     11,499,329       153,020             11,652,349  

Property and equipment, net

     9,602       284,859             294,461  

Restricted Cash

     —         50,773             50,773  

Other assets

     —         6,000             6,000  

Goodwill

     —         —       47,432 (a)     47,432  

TOTAL ASSETS

   $ 11,508,931     $ 494,652           $ 12,051,015  
    


 


       


LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)

                              

CURRENT LIABILITIES

                              

Accounts payable

   $ 31,552     $ 16,562           $ 48,114  

Accrued expenses

     6,862       20,020             26,882  

Payroll liabilities

     —         30,332             30,332  
    


 


       


TOTAL CURRENT LIABILITIES

     38,414       66,914             105,328  

Notes payable

     —         2,148,750     (2,148,750 )(b)     —    

Minority Interest

     —         —       475,170 (a)     475,170  
    


 


       


TOTAL LIABILITIES

     38,414       2,215,664             580,498  

SHAREHOLDERS’ EQUITY

                              

Common Stock

     13,551       13,670     (13,670 )(a,b)     13,551  

Preferred Stock

             3,000,000     (3,000,000 )(a,b)     —    

Additional paid-in capital

     11,934,019       —               11,934,019  

Accumulated deficit during the development stage

     (477,053 )     (4,734,682 )   4,734,682 (a)     (477,053 )
    


 


       


TOTAL SHAREHOLDERS’ EQUITY (DEFICIT)

     11,470,517       (1,721,012 )           11,470,517  
    


 


       


TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)

   $ 11,508,931     $ 494,652           $ 12,051,015  
    


 


       



(a) To eliminate stockholders’ equity.
(b) Represents conversion of notes payable into equity at date of transaction.


Arrowhead Research Corporation

Pro Forma Condensed, Combined Statement of Operations

For the Year Ended September 30, 2003

 

     For the period from
inception (May 7,
2003) through
September 30, 2003


    For the year
ended
December 31,
2003


             
     Arrowhead

    Insert

    Adjustments

    Pro Forma

 

REVENUE

   $ —       $ 377,212           $ 377,212  

OPERATING EXPENSES

                              

Salaries

     25,000       849,837             874,837  

Consulting

     25,000       186,984             211,894  

General and administrative expenses

     41,063       310,969             352,032  

Research and development

     3,375       696,581             699,956  
    


 


       


TOTAL OPERATING EXPENSES

     94,438       2,044,371             2,138,809  

OPERATING LOSS

     (94,438 )     (1,667,159 )           (1,761,597 )
    


 


       


OTHER INCOME (EXPENSES)

                              

Interest income

     —         6,480             6,480  

Interest expense

     —         (97,867 )   97,867 (a)     —    
    


 


       


TOTAL OTHER INCOME (EXPENSES)

     —         (91,387 )           6,480  

Minority interest

                   624,415 (b)     624,415  

Provision for income taxes

     800       —               800  
    


 


       


NET LOSS

   $ (95,238 )   $ (1,758,546 )         $ (1,131,502 )
    


 


       



(a) Reflects elimination of interest expense totaling $97,867 for the year ended December 31, 2003 upon the conversion of all amounts owing under these notes into 4,000,000 shares of Insert Therapeutics’ common stock in June 2004. Conversion of these notes was a condition of the stock sale.
(b) Represents the minority interest in the loss of Insert.


Arrowhead Research Corporation

Pro Forma Condensed, Combined Statement of Operations

For the Six Months Ended March 31, 2004

(Unaudited)

 

     For the six
months
ended March
31, 2004


   

For the

three

months
ended
December 31,

2003


    For the
three
months
ended
March 31,
2004


             
     Arrowhead

    Insert

    Insert

    Adjustments

    Pro Forma

 

REVENUE

   $ —       $ 22,571     $ 13,722           $ 36,293  

OPERATING EXPENSES

                                      

Salaries

     40,000       224,333       218,044             482,377  

Consulting

     58,475       31,488       39,238             129,201  

General and administrative expenses

     373,095       34,091       43,227             450,413  

Research and development

     202,410       136,108       63,776             402,294  
    


 


 


       


TOTAL OPERATING EXPENSES

     673,980       426,020       364,285             1,464,285  

OPERATING LOSS

     (673,980 )     (403,449 )     (350,563 )           (1,427,992 )
    


 


 


       


OTHER INCOME (EXPENSES)

                                      

Loss on disposition of building and equipment

     (23,331 )     0       0             (23,331 )

Interest income

     8,668       703       483             9,854  

Interest expense

     —         (34,228 )     (42,880 )   77,108 (a)     —    

Unrealized gains (losses) on marketable securities

     307,628       —         —               307,628  
    


 


 


       


TOTAL OTHER INCOME (EXPENSES)

     292,965       (33,525 )     (42,397 )           294,151  

Minority interest

                           283,063 (b)     283,063  

Provision for income taxes

     800       —                       800  
    


 


               


NET LOSS

   $ (381,815 )   $ (436,974 )   $ (392,960 )         $ (851,578 )
    


 


 


       



(a) Reflects elimination of interest expense totaling $77,108 for the six months ended March 31, 2003 upon the conversion of all amounts owing under these notes into 4,000,000 shares of Insert Therapeutics’ common stock per share in June 2004. Conversion of these notes was a condition of the stock sale.
(b) Represents the minority interest in the loss of Insert.